A New Era in Oncology

Pioneering Approach

We are a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer. We apply our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.

Learn more
molecular structure

ProTide Technology

We harness the power of phosphoramidate chemistry to develop next-generation chemotherapeutics designed to overcome the key cancer resistance mechanisms and other limitations of existing nucleoside analogs.

Discover More

Mission Statement

“To significantly improve the survival outcomes for patients by transforming chemotherapy and pioneering a new era in oncology”.

Hugh S. Griffith - Founder & CEO

Learn more
Hugh Griffith CEO

To Transform Chemotherapy and Pioneer a New Era in Oncology

Biology for the Future

NuCana features on a news and current affairs style series by ITN Productions and the Royal Society of Biology (RSB).

Jigsaw pieces

Leadership Team

Our highly experienced team has a successful track record of building global biopharmaceutical companies and developing new life-saving medicines for patients.

Read More

Latest News

Edinburgh: May 2024

NuCana to Present at the Jefferies Global Healthcare Conference

More News

Upcoming Events

Edinburgh: June 2024

Jefferies Global Healthcare Conference
New York, NY
Jun 05 - Jun 06, 2024

Past Events

Contact Details

Global Headquarters

3 Lochside Way, Edinburgh, EH12 9DT, UK


+ 44 131 357 1111

US Office

275 Grove Street, Newton, MA 02466


+1 617 663 5708

* These fields are required.